thalidomide has been researched along with Acute Promyelocytic Leukemia in 6 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate whether granulocyte-macrophage colony-stimulating factor (GM-CSF) with or without thalidomide can induce apoptosis and differentiation of HL-60 acute promyelocytic leukemia cell line in vitro." | 7.73 | Differentiating effect of thalidomide and FGM-CS combination on HL-60 acute promyelocytic leukemia cells. ( Avcu, F; Beyzadeoglu, M; Pekel, A; Ural, AU; Yilmaz, MI; Zerman, M, 2006) |
| "To investigate whether granulocyte-macrophage colony-stimulating factor (GM-CSF) with or without thalidomide can induce apoptosis and differentiation of HL-60 acute promyelocytic leukemia cell line in vitro." | 3.73 | Differentiating effect of thalidomide and FGM-CS combination on HL-60 acute promyelocytic leukemia cells. ( Avcu, F; Beyzadeoglu, M; Pekel, A; Ural, AU; Yilmaz, MI; Zerman, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bunce, CM | 1 |
| Khanim, FL | 1 |
| Drayson, MT | 1 |
| Asakura, H | 1 |
| Winter, GE | 1 |
| Buckley, DL | 1 |
| Paulk, J | 1 |
| Roberts, JM | 1 |
| Souza, A | 1 |
| Dhe-Paganon, S | 1 |
| Bradner, JE | 1 |
| Sekeres, MA | 1 |
| Ural, AU | 1 |
| Avcu, F | 1 |
| Zerman, M | 1 |
| Yilmaz, MI | 1 |
| Pekel, A | 1 |
| Beyzadeoglu, M | 1 |
| Nishimura, K | 1 |
| Hashimoto, Y | 1 |
| Iwasaki, S | 1 |
3 reviews available for thalidomide and Acute Promyelocytic Leukemia
| Article | Year |
|---|---|
Does the pursuit of scientific excellence serve or hamper translational medical research: an historical perspective from hematological malignancies.
Topics: Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; | 2022 |
[Thrombosis and DIC in hematological malignancies].
Topics: Annexin A2; Antineoplastic Agents; Asparaginase; Cytokines; Disseminated Intravascular Coagulation; | 2014 |
Arsenic trioxide as a treatment for myelodysplastic syndrome.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Clinical Tr | 2006 |
3 other studies available for thalidomide and Acute Promyelocytic Leukemia
| Article | Year |
|---|---|
DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation.
Topics: Adaptor Proteins, Signal Transducing; Animals; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Crys | 2015 |
Differentiating effect of thalidomide and FGM-CS combination on HL-60 acute promyelocytic leukemia cells.
Topics: Antigens, Differentiation; Apoptosis; Cell Differentiation; Cell Proliferation; Granulocyte-Macropha | 2006 |
Enhancement of phorbol ester-induced production of tumor necrosis factor alpha by thalidomide.
Topics: Cell Line; Drug Synergism; Humans; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leuke | 1994 |